Eton Pharmaceuticals, Inc. ETON Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| License | $0-100% | $3.29M+557% | $3.29M+557% | $3.79M— | $3.79M-31.2% | |
| Product Sales And Royalties | $86.93M+95.2% | $76.66M+99.1% | $67.03M+96.1% | $54.4M+73.3% | $44.54M+54.6% | |
| Cost of Goods Sold by Product | ||||||
| License | $0-100% | $825K+206% | $825K-35.0% | $1.1M+9.5% | $1.1M+9.5% | |
| Product Sales And Royalties | $39.32M+107% | $36.39M+137% | $33.38M+160% | $22.52M+92.3% | $18.97M+79.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Eton Pharmaceuticals, Inc. break its business down?
- Eton Pharmaceuticals, Inc. (ETON) reports revenue by product across 2 parts — License and Product Sales And Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Eton Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Eton Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
